another recent paper using this approach
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0397-z
The hypothesis is that engineered MSCs which injected intravenously into the tumor-bearing mice would specifically migrate to tumor site and secrete Tandab (CD3/CD19) which recruits T cells to exhibit a potent antitumor immunity in combination with an IDO pathway inhibitor D-1MT. And results presented here support the feasibility of this strategy.
We have demonstrated in this study that human UC-MSCs can be acted as cell-based delivery vehicles for the treatment of B cell lymphoma. Tandab (CD3/CD19) secreted from UC-MSCs effectively redirected T cells to inhibit the growth of Raji lymphoma in mouse models in combination with D-1MT. Our findings indicate that the use of UC-MSCs as vehicles for engineered-antibodies combined with immunoregulatory agents represents a potential clinical application of gene therapy for cancers.
MSCs and Breast Canvcer, page-4
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $36.13M |
Open | High | Low | Value | Volume |
20.5¢ | 20.5¢ | 20.0¢ | $8.749K | 42.75K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 19130 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 19130 | 0.190 |
1 | 15000 | 0.185 |
2 | 10055 | 0.180 |
1 | 285 | 0.175 |
1 | 6050 | 0.165 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 20000 | 1 |
0.205 | 38856 | 1 |
0.210 | 60000 | 1 |
0.220 | 17664 | 2 |
0.235 | 3225 | 1 |
Last trade - 13.09pm 06/09/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |